After randomization, suppression of the psoriasis molecular signature (Figure 4A) and IL-17A transcripts in skin (eFigure 5 in Supplement 2) was not maintained in the abatacept group vs the ustekinumab group at week 24 and/or week 40; this result is consistent with the earlier relapse time from enrollment in the abatacept group vs the ustekinumab group (Figure 2A). Here, IL17A is linked to psoriasis.